Flatiron Health Announces Collaborative Research to be Presented at ASCO 2017 Annual Meeting
Flatiron Health today announced four abstracts accepted for presentation at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting to be held June 2-6 in Chicago. The abstracts represent initial results of ongoing collaborations with Flatiron’s research and academic partners.
The research to be presented includes a retrospective observational study with the Food & Drug Administration — the first findings from the collaboration announced in 2016. Initial results from Foundation Medicine and Flatiron’s Clinico-Genomic Database project will also be shown as a part of a poster discussion presentation. Finally, Yale and Flatiron partnered on two studies examining racial, age and insurance disparities in cancer care. The presentation schedule and links to abstracts can be found below.
Rates of PD-L1 expression testing in US community-based oncology practices for patients with metastatic non-small cell lung cancer (mNSCLC) receiving nivolumab or pembrolizumab (Abstract #11596; Poster #296)
Presenting Author: Sean Khozin, MD, MPH, U.S. Food and Drug Administration Date/Time: Saturday, June 3 — 1:15PM – 4:45PM CDT Session: Tumor Biology
Racial disparities in the use of programmed death 1 (PD-1) checkpoint inhibitors (Abstract 3068; Poster #163)
Presenting Author: Jeremy O’Connor, MD, Yale School of Medicine Date/Time: Monday, June 5 — 8:00AM-11:30AM CDT Session: Developmental Therapeutics – Immunotherapy
Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer (Abstract #6563; Poster #385)
Presenting Author: Carolyn Jean Presley, MD, Yale Cancer Center Date/Time: Monday, June 5 — 1:15 PM – 4:45 PM CDT Session: Health Services Research, Clinical Informatics, and Quality of Care
Poster Discussion Presentation
Development and validation of a real-world clinico-genomic database (Abstract #2514; Poster #6)
Presenting Author: Gaurav Singal, MD, Foundation Medicine, Inc. Date/Time: Monday, June 5 — 11:30AM – 12:45PM CDT (Arie Crown Theater) Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
A complete list of Flatiron’s accepted abstracts can be found here. To learn more about Flatiron Health, visit our booth during the conference at #4031.
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research centers and over 15 of the top therapeutic oncology companies. For more information, please visit flatiron.com or follow us @FlatironHealth.